TNFRSF4 and pancreatic neoplasm: Experimental work demonstrated that combined treatment with an anti-PD-1 Ab and an anti-OX40 agonist resulted in longer survival compared to monotherapy with either anti-PD-1 Ab or anti-OX40 in a pancreatic cancer mouse model [117].